Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG (NCT07649187) | Clinical Trial Compass
CompletedNot Applicable
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
Taiwan19 participantsStarted 2024-01-01
Plain-language summary
This study aimed to examine whether baseline depressive tendency independently predicts post-counseling clinical outcomes in patients with thymoma-associated MG. This single-group pre-post exploratory pilot study enrolled patients with thymoma-associated MG who received eight sessions of Gestalt-oriented psychological counseling. Depressive tendency was defined as a baseline Patient Health Question-naire-9 (PHQ-9) score ≥10. Clinical outcomes, including the Myasthenia Gravis Activities of Daily Living scale (MG-ADL), Myasthenia Gravis Quality of Life 15-item scale (MG-QoL15), and mental BMI (mBMI), were assessed before and after the intervention. Multivariable regression analyses were performed to evaluate whether baseline clinical severity independently predicted post-intervention outcomes after sequential adjustment for baseline scores, age, and sex.
Who can participate
Age range
20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. A confirmed diagnosis of MG associated with thymoma and prior completion of surgical treatment
. Age ≥ 20 years
. Ability to communicate clearly and provide reliable responses
. Absence of cognitive impairment or severe psychiatric illness that could interfere with participation
. Willingness to participate in the study with provision of written informed consent
Exclusion criteria
. The absence of a confirmed diagnosis of myasthenia gravis
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial specifically studied people with thymoma-associated myasthenia gravis who also had depressive tendencies — does my situation match that profile closely enough that the findings might be relevant to my care?
2The trial measured changes in daily functioning using the MG-ADL scale and depression using the PHQ-9 — have my own scores on these tools been assessed, and could they help guide whether counseling should be part of my treatment plan?
3Since this study is now completed, have the results been published or shared anywhere, and what did they suggest about whether counseling actually improved quality of life or mood for patients like me?
4This trial focused on a counseling intervention rather than a drug — given everything else I'm managing with myasthenia gravis, how realistic would it be to add a structured counseling program to my current care, and is that something you could help coordinate?
5If depression is a real concern alongside my MG, are there other evidence-based options you'd recommend comparing against what this trial tested, so we can figure out the best approach for my specific situation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score from baseline to post-intervention
Timeframe: Baseline to 4 months
2
Change in Myasthenia Gravis Quality of Life 15-item (MG-QOL15) Score from baseline to post-intervention
Timeframe: Baseline to 4 months
3
Change in the indicator of mental health BMI on well-being (mBMI) Score from baseline to post-intervention
Timeframe: Baseline to 4 months
4
Change in the indicator of mental health BMI on well-being (PHQ-9) Score from baseline to post-intervention
. Failure to confirm thymoma on postoperative pathological examination
. Inability to communicate adequately in Mandarin, Taiwanese, English, or written form
. The presence of conditions that could compromise verbal communication or regular participation in counseling sessions, such as significant traumatic brain injury, severe psychiatric disorders, or cognitive impairment